Valuation: ALLOVIRPAR

Market Cap 49.21M 43.71M 40.88M 37.25M 70.13M 4.74B 71.09M 494M 191M 2.41B 185M 181M 7.75B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -61.35M -57.38M -52.29M -98.44M -6.65B -99.79M -694M -269M -3.39B -259M -254M -10.88B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-1.38%
Current month-70.95%
Current year-70.95%
3 years 2.76
Extreme 2.76
57.15
5 years 2.76
Extreme 2.76
606.74
10 years 2.76
Extreme 2.76
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -169M -158M -144M -271M -18.33B -275M -1.91B -741M -9.34B -715M -699M -29.99B -58.77M -52.2M -48.81M -44.48M -83.75M -5.66B -84.9M -591M -229M -2.88B -221M -216M -9.26B
Net Debt -157M -139M -130M -118M -223M -15.07B -226M -1.57B -609M -7.67B -588M -575M -24.65B -118M -105M -98.25M -89.54M -169M -11.39B -171M -1.19B -460M -5.8B -444M -434M -18.63B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
26-10-01 US$2.850 -1.38%
26-09-30 US$2.890 -0.34%
26-09-29 US$2.900 +1.93%
26-09-28 US$2.845 -2.57%
26-09-25 US$2.920 -4.89%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock